Bonora S, Calcagno A, Gonzalez de Requena D, Bargiacchi O, Di Perri G
Clinica di Malattie Infettive, Universita di Torino, Italy.
Infez Med. 2006 Jun;14(2):61-70.
Options for antiretroviral therapy in patients infected with HIV continue to expand as new drugs are integrated into treatment regimens. Nucleoside/nucleotide reverse transcriptase inhibitors (Nt/NRTIs) remain the backbone of highly active antiretroviral therapy (HAART). Although this is the oldest class of antiretrovirals, pharmacokinetic and pharmacodynamic properties have been less studied as compare to protease inhibotors (PIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs). The aim of this article is to review the current status of clinical pharmacology onf Nt/NRTIs, highlighting the issues with clinical interest. Therefore, implications of intracellular pharmacokinetics on dosing schedule, potential for drug-drug interaction and pharmacodynamics is discussed.
随着新药被纳入治疗方案，感染HIV患者的抗逆转录病毒治疗选择持续增加。核苷/核苷酸逆转录酶抑制剂（Nt/NRTIs）仍然是高效抗逆转录病毒治疗（HAART）的基础。尽管这是最古老的一类抗逆转录病毒药物，但与蛋白酶抑制剂（PIs）和非核苷逆转录酶抑制剂（NNRTIs）相比，其药代动力学和药效学特性的研究较少。本文旨在综述Nt/NRTIs的临床药理学现状，突出具有临床意义的问题。因此，将讨论细胞内药代动力学对给药方案的影响、药物相互作用的可能性以及药效学。
